Health Trials

Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).

Participants needed: 60
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: CRISPR Therapeutics AGUpdated: Jun 15, 2026Locations: 3
Eligibility criteria

Age ≥18 years. [+5]

Prior treatment with anti-CD19 therapy or any gene therapy or genetically modifi... [+10]

Read more
Status: Recruiting

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias

This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.

Participants needed: 90
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: CRISPR Therapeutics AGUpdated: May 22, 2026Locations: 18
Eligibility criteria

Age of ≥18 and ≤75 years at the time of signing the informed consent. [+5]

Participants with familial chylomicronemia syndrome (FCS). Some exceptions may a... [+6]

Read more
Status: Recruiting

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.

Participants needed: 120
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: CRISPR Therapeutics AGUpdated: Nov 14, 2025Locations: 7
Eligibility criteria

Age ≥18 years. [+4]

Prior allogeneic hematopoietic stem cell transplant (HSCT). [+8]

Read more